Titan Biotech Intrinsic Value
Titan Biotech (TITANBIO) median intrinsic value is ₹309.82 from 10 valuation models (range ₹123–₹640), vs current price ₹410.00 — -24.4% downside (Trading Above Calculated Value), margin of safety -32.3%. For current market price and key ratios, visit TITANBIO company profile.
TITANBIO Valuation Methods Summary — DCF, Graham Number & P/E
Titan Biotech intrinsic value across 10 models vs current price ₹410.00 — upside/downside and value range per method. Browse TITANBIO complete financial for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹451.20 | ₹360.96 - ₹541.44 | +10.0% | EPS: ₹37.60, Sector P/E: 12x |
| Book Value Method | asset | ₹191.25 | ₹172.12 - ₹210.38 | -53.4% | Book Value/Share: ₹191.25, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹224.00 | ₹201.60 - ₹246.40 | -45.4% | Revenue/Share: ₹280.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹322.94 | ₹290.65 - ₹355.23 | -21.2% | EBITDA: ₹44.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹200.55 | ₹160.44 - ₹240.66 | -51.1% | CF Growth: 1.3%, Discount: 15% |
| PEG Ratio Method | growth | ₹240.64 | ₹216.58 - ₹264.70 | -41.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹309.82 | ₹278.84 - ₹340.80 | -24.4% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹640.00 | ₹576.00 - ₹704.00 | +56.1% | ROE: 20.9%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹382.50 | ₹344.25 - ₹420.75 | -6.7% | EPS: ₹37.60, BVPS: ₹191.25 |
| Dividend Yield Method | dividend | ₹123.00 | ₹110.70 - ₹135.30 | -70.0% | DPS: ₹2.00, Target Yield: 3.5% |
TITANBIO Intrinsic Value vs Market Price — All Valuation Models
Titan Biotech fair value range ₹123–₹640 vs current market price ₹410.00 across 10 valuation models. Compare with TITANBIO DCF to assess whether the stock is under or overvalued.
TITANBIO Intrinsic Value Analysis — Undervalued or Overvalued?
Titan Biotech median intrinsic value ₹309.82, current price ₹410.00 — Trading Above Calculated Value by 24.4%, margin of safety -32.3%.
What is the intrinsic value of TITANBIO?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Titan Biotech (TITANBIO) is ₹309.82 (median value). With the current market price of ₹410.00, this represents a -24.4% variance from our estimated fair value.
The valuation range spans from ₹123.00 to ₹640.00, indicating ₹123.00 - ₹640.00.
Is TITANBIO undervalued or overvalued?
Based on our multi-method analysis, Titan Biotech (TITANBIO) appears to be trading above calculated value by approximately 24.4%.
TITANBIO Financial Health — Key Ratios vs Industry Benchmarks
Titan Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 19.75 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.14 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 20.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.28x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
TITANBIO Cash Flow Quality — Operating & Free Cash Flow
Titan Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹20 Cr | ₹15 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹21 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹21 Cr | ₹11 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹22 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹19 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |